Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.38), versus ($0.12) reported last year.

As of March 31, 2018, cash and cash equivalents totaled $21.7 million, compared to $23.9 million as of December 31, 2017. The decrease of $2.2 million was primarily due to net cash used in operating activities.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.